Learn how GA4GH helps expand responsible genomic data use to benefit human health.
Learn how GA4GH helps expand responsible genomic data use to benefit human health.
Our Strategic Road Map defines strategies, standards, and policy frameworks to support responsible global use of genomic and related health data.
Discover how a meeting of 50 leaders in genomics and medicine led to an alliance uniting more than 5,000 individuals and organisations to benefit human health.
GA4GH Inc. is a not-for-profit organisation that supports the global GA4GH community.
To guide our collaborative, globe-spanning alliance, GA4GH relies on a Standards Steering Committee and an Executive Committee.
The Funders Forum brings together organisations that offer both financial support and strategic guidance.
The EDI Advisory Group responds to issues raised in the GA4GH community, finding equitable, inclusive ways to build products that benefit diverse groups.
Distributed across four Host Institutions, our staff team supports the mission and operations of GA4GH.
Curious who we are? Meet the people and organisations across six continents who make up GA4GH.
More than 500 organisations connected to genomics — in healthcare, research, patient advocacy, industry, and beyond — have signed onto the mission and vision of GA4GH as Organisational Members.
These core Organisational Members are genomic data initiatives that have committed resources to guide GA4GH work and pilot our products.
This subset of Organisational Members whose networks or infrastructure align with GA4GH priorities has made a long-term commitment to engaging with our community.
Local and national organisations assign experts to spend at least 30% of their time building GA4GH products.
Anyone working in genomics and related fields is invited to participate in our inclusive community by creating and using new products.
Wondering what GA4GH does? Learn how we find and overcome challenges to expanding responsible genomic data use for the benefit of human health.
Study Groups define needs. Participants survey the landscape of the genomics and health community and determine whether GA4GH can help.
Work Streams create products. Community members join together to develop technical standards, policy frameworks, and policy tools that overcome hurdles to international genomic data use.
GIF solves problems. Organisations in the forum pilot GA4GH products in real-world situations. Along the way, they troubleshoot products, suggest updates, and flag additional needs.
NIF finds challenges and opportunities in genomics at a global scale. National programmes meet to share best practices, avoid incompatabilities, and help translate genomics into benefits for human health.
Communities of Interest find challenges and opportunities in areas such as rare disease, cancer, and infectious disease. Participants pinpoint real-world problems that would benefit from broad data use.
See all our products — always free and open-source. Do you work on cloud genomics, data discovery, user access, data security or regulatory policy and ethics? Need to represent genomic, phenotypic, or clinical data? We’ve got a solution for you.
All GA4GH standards, frameworks, and tools follow the Product Development and Approval Process before being officially adopted.
Learn how other organisations have implemented GA4GH products to solve real-world problems.
Help us transform the future of genomic data use! See how GA4GH can benefit you — whether you’re using our products, writing our standards, subscribing to a newsletter, or more.
Help create new global standards and frameworks for responsible genomic data use.
Align your organisation with the GA4GH mission and vision.
Solve your real-world data problems with support from this valuable network of global institutions.
Work with like-minded groups committed to better data use in areas like rare disease, cancer, and infectious disease.
Share your thoughts on all GA4GH products currently open for public comment.
Solve real problems by aligning your organisation with the world’s genomics standards. We offer software dvelopers both customisable and out-of-the-box solutions to help you get started.
Learn more about upcoming GA4GH events. See reports and recordings from our past events.
Speak directly to the global genomics and health community while supporting GA4GH strategy.
Be the first to hear about the latest GA4GH products, upcoming meetings, new initiatives, and more.
Questions? We would love to hear from you.
Read news, stories, and insights from the forefront of genomic and clinical data use.
Attend an upcoming GA4GH event, or view meeting reports from past events.
See new projects, updates, and calls for support from the Work Streams.
Read academic papers coauthored by GA4GH contributors.
Listen to our podcast OmicsXchange, featuring discussions from leaders in the world of genomics, health, and data sharing.
Check out our videos, then subscribe to our YouTube channel for more content.
View the latest GA4GH updates, Genomics and Health News, Implementation Notes, GDPR Briefs, and more.
Discover all things GA4GH: explore our news, events, videos, podcasts, announcements, publications, and newsletters.
11 Aug 2022
To aid researchers and clinicians in developing clear and digestible consent forms, the GA4GH Regulatory and Ethics Work Stream (REWS) has developed Consent Clauses for Large Scale Initiatives and Clinical Genomic Consent Clauses. These latest additions complete the REWS Consent Toolkit
Informed consent undergirds the practices of research and medical care. Yet patient and participant consent forms are often long documents that are difficult to understand, leading to confusion, suspicion, or even serious ethical harm. Two templates from the Global Alliance for Genomics and Health (GA4GH) aim to help researchers and clinicians draft more accessible consent forms.
As genomic testing becomes an integral part of research and healthcare, participants and patients may have a host of questions — from what genomic sequencing is in the first place, to what results and information will be reported back to them, to how the data will be stored to protect their identity and privacy.
To aid researchers and clinicians in developing clear and digestible consent forms, the GA4GH Regulatory and Ethics Work Stream (REWS) has developed Consent Clauses for Large Scale Initiatives and Clinical Genomic Consent Clauses.
Approved by the GA4GH Standards Steering Committee earlier this year, these latest additions complete the Consent Toolkit — a series of template clauses that the genomics and health community can reference and adapt when drafting consent forms for genomic studies or testing. Other resources in the Consent Toolkit include Familial Consent Clauses, Pediatric Consent Clauses, Consent Clauses for Genomic Research, and the Model Consent Clauses for Rare Disease Research.
The Consent Clauses for Large Scale Initiatives document provides an inventory of template consent clauses for studies involving large scale data collection, such as biobank or population studies.
“We hope these clauses can serve as a resource for researchers,” said Meg Doerr, Director of Applied Ethical, Legal, and Social Implication Research at Sage Bionetworks and Co-Lead of the Consent Clauses for Large Scale Initiatives effort. “We reviewed a range of consent clauses from different studies and countries and distilled them into simple, accessible language that researchers can customise for their specific context.”
Altogether, the REWS Consent Task Force collated consent forms used by more than a dozen national and multinational initiatives.
“We then categorised our inventory by questions a participant may have,” continued Susan E. Wallace, Honorary Lecturer at the University of Leicester, UK, and a contributing member of the Task Force. “By doing so, we hope to encourage researchers to prioritise and focus on the participant experience.”
The clause catalogue provides sample language to help researchers create a consent form. For example, clauses describe the study, outline what researchers will ask the participant to do, detail what actions they will take on the DNA sample or information, and share who else might have access to the data.
The Clinical Genomic Consent Clauses document is a typology of clauses for authorising genomic testing as part of a patient’s clinical care. With growing frequency, clinicians are integrating genomic sequencing into diagnosis and precision medicine. It is vital to help patients understand the purpose of this genomic testing and their results. As such, the consent clauses are intentionally brief and concise.
“It is important to foster trust and transparency, especially when people need to make important decisions related to their personal health and medical care,” said Bartha Maria Knoppers, Director of the Centre of Genomics and Policy at McGill University and Co-Lead in developing the Clinical Genomic Consent Clauses. “Unfortunately, many hospital settings don’t have opportunities for in-depth communication with the patient. We hope these clauses can provide that starting point.”
To build the typology, the Task Force analysed more than 12 genomic consent forms currently in use in healthcare systems around the world.
The template clauses focus on the impact of genomic testing on the patient, providing sample language on what information will be reported back to the patient, how to understand the results, what happens when unexpected information is discovered, and when the provider may recontact the patient in the future. The resource also includes a sample authorisation form for reference.
Similar to the other consent clauses in the Consent Toolkit, the Clinical Genomics document also explains the basics of genomic testing, including how the patient’s sample and data will be stored and shared, as well as procedures for protecting patient privacy.
Participant and patient consents play a crucial role in responsible data exchange and secondary use of health data for research.
To enable accurate and efficient data sharing, researchers and clinicians can represent clauses from the Consent Toolkit in a machine-readable way, using the GA4GH Machine-Readable Consent Guidance — a partnership between REWS and the Data Use and Researcher Identities (DURI) Work Stream.
Writing consent forms that computers can read enables a continual learning system between research and healthcare. In other words, when a patient’s consents clearly and accurately map to their data, authorised researchers can access the data to fuel new research and insights into human health and disease.
“With Consent Clauses for Large Scale Initiatives and Clinical Genomic Consent Clauses now part of the Consent Toolkit, we can empower not only participant and patient communities in making informed decisions, but also the research and health communities to become trusted partners in the process,” said Kristina Kékesi-Lafrance, Clinical Ethicist at the Montréal West Island Integrated University Health and Social Services Centre and Co-Lead of the Clinical Genomic Consent Clauses effort.